BIOMAT Database Logo BIOMAT Database Logo

Protective immunity against bovine leukaemia virus (BLV) induced in carrier sheep by inoculation with a vaccinia virus-BLV env recombinant: association with cell-mediated immunity. 1991

K Ohishi, and H Suzuki, and T Yamamoto, and T Maruyama, and K Miki, and Y Ikawa, and S Numakunai, and K Okada, and K Ohshima, and M Sugimoto
Corporate Research and Development Laboratory, Tonen Corporation, Saitama, Japan.

The effects of vaccination of sheep with a recombinant vaccinia virus (rVV) expressing the bovine leukaemia virus (BLV) envelope glycoprotein (gp60) were studied by determining BLV titres in peripheral blood leukocytes after vaccination and challenge. The proliferation of BLV was suppressed markedly, not only when rVV was inoculated prior to challenge with BLV, but also when it was inoculated after challenge. These results indicate that vaccination with rVV induces protective immunity that can suppress the growth of BLV in carrier animals. Since rVV induced a strong anti-BLV delayed-type hypersensitivity response without producing detectable levels of binding or neutralizing antibodies, and there was no apparent correlation between the humoral immune response and BLV proliferation, a cell-mediated immune response was assumed to play a major role in protective immunity.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007700 Kinetics The rate dynamics in chemical or physical systems.
D007942 Leukemia, Experimental Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues. Experimental Leukemia,Experimental Leukemias,Leukemia Model, Animal,Leukemias, Experimental,Animal Leukemia Model,Animal Leukemia Models,Leukemia Models, Animal
D007962 Leukocytes White blood cells. These include granular leukocytes (BASOPHILS; EOSINOPHILS; and NEUTROPHILS) as well as non-granular leukocytes (LYMPHOCYTES and MONOCYTES). Blood Cells, White,Blood Corpuscles, White,White Blood Cells,White Blood Corpuscles,Blood Cell, White,Blood Corpuscle, White,Corpuscle, White Blood,Corpuscles, White Blood,Leukocyte,White Blood Cell,White Blood Corpuscle
D008297 Male Males
D001909 Leukemia Virus, Bovine The type species of DELTARETROVIRUS that causes a form of bovine lymphosarcoma (ENZOOTIC BOVINE LEUKOSIS) or persistent lymphocytosis. BLV,Bovine Leukemia Virus,Cattle Leukemia Virus,Leukemia Virus, Cattle,Virus, Bovine Leukemia,Virus, Cattle Leukemia
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012756 Sheep Any of the ruminant mammals with curved horns in the genus Ovis, family Bovidae. They possess lachrymal grooves and interdigital glands, which are absent in GOATS. Ovis,Sheep, Dall,Dall Sheep,Ovis dalli
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.

Related Publications

K Ohishi, and H Suzuki, and T Yamamoto, and T Maruyama, and K Miki, and Y Ikawa, and S Numakunai, and K Okada, and K Ohshima, and M Sugimoto
[Protective effect against BLV by inoculation with a vaccinia virus-BLV env recombinant].
December 1992, Uirusu,
K Ohishi, and H Suzuki, and T Yamamoto, and T Maruyama, and K Miki, and Y Ikawa, and S Numakunai, and K Okada, and K Ohshima, and M Sugimoto
Protective immunity against foot-and-mouth disease virus induced by a recombinant vaccinia virus.
April 2000, Vaccine,
K Ohishi, and H Suzuki, and T Yamamoto, and T Maruyama, and K Miki, and Y Ikawa, and S Numakunai, and K Okada, and K Ohshima, and M Sugimoto
Protective effects of vaccination with bovine leukemia virus (BLV) Tax DNA against BLV infection in sheep.
November 2003, The Journal of veterinary medical science,
K Ohishi, and H Suzuki, and T Yamamoto, and T Maruyama, and K Miki, and Y Ikawa, and S Numakunai, and K Okada, and K Ohshima, and M Sugimoto
Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria.
June 1993, Proceedings of the National Academy of Sciences of the United States of America,
K Ohishi, and H Suzuki, and T Yamamoto, and T Maruyama, and K Miki, and Y Ikawa, and S Numakunai, and K Okada, and K Ohshima, and M Sugimoto
T cell-mediated destruction of bovine leukemia virus-infected peripheral lymphocytes by bovine leukemia virus env-vaccinia recombinant vaccine.
March 1996, AIDS research and human retroviruses,
K Ohishi, and H Suzuki, and T Yamamoto, and T Maruyama, and K Miki, and Y Ikawa, and S Numakunai, and K Okada, and K Ohshima, and M Sugimoto
An effective peptide vaccine to eliminate bovine leukaemia virus (BLV) infected cells in carrier sheep.
August 1996, Vaccine,
K Ohishi, and H Suzuki, and T Yamamoto, and T Maruyama, and K Miki, and Y Ikawa, and S Numakunai, and K Okada, and K Ohshima, and M Sugimoto
Protection of sheep against bovine leukemia virus (BLV) infection by vaccination with recombinant vaccinia viruses expressing BLV envelope glycoproteins: correlation of protection with CD4 T-cell response to gp51 peptide 51-70.
April 1993, Journal of virology,
K Ohishi, and H Suzuki, and T Yamamoto, and T Maruyama, and K Miki, and Y Ikawa, and S Numakunai, and K Okada, and K Ohshima, and M Sugimoto
Recombinant vaccinia virus expression of the bovine leukaemia virus envelope gene and protection of immunized sheep against infection.
March 1991, Vaccine,
K Ohishi, and H Suzuki, and T Yamamoto, and T Maruyama, and K Miki, and Y Ikawa, and S Numakunai, and K Okada, and K Ohshima, and M Sugimoto
Peptide-based bovine leukemia virus (BLV) vaccine that induces BLV-Env specific Th-1 type immunity.
April 1997, Leukemia,
K Ohishi, and H Suzuki, and T Yamamoto, and T Maruyama, and K Miki, and Y Ikawa, and S Numakunai, and K Okada, and K Ohshima, and M Sugimoto
The possibility of specific protection against bovine leukaemia virus infection and bovine leukaemia with inactivated BLV.
January 1983, The British veterinary journal,
Copied contents to your clipboard!